Cancer Biomarkers
Genetic mutations, protein markers, and molecular targets that guide precision oncology treatment decisions.
Biomarkers
Cancer Biomarkers
- MET
MET
MET exon 14 skipping mutations and MET amplification in NSCLC. Targeted by capmatinib, tepotinib, savolitinib.
View Biomarker MLL Rearranged
KMT2A (MLL) rearrangements in acute leukemias. Targeted by emerging menin inhibitors (revumenib, ziftomenib).
View Biomarker- Featured
MSI-H
Microsatellite Instability High. Indicates mismatch repair deficiency. Predicts strong response to checkpoint inhibitors across cancer types.
View Biomarker - NPM1
NPM1
Common AML mutation, generally favorable prognosis when isolated. Drives sensitivity to menin inhibitors and venetoclax.
View Biomarker - NTRK1/2/3
NTRK
NTRK gene fusions occur rarely across cancer types. Tumor-agnostic indication for larotrectinib and entrectinib.
View Biomarker - FeaturedCD274
PD-L1
Programmed Death Ligand 1. Expression predicts response to PD-1/PD-L1 checkpoint inhibitors in many cancers.
View Biomarker - PIK3CA
PIK3CA
Most commonly mutated kinase in cancer. Alpelisib targets PIK3CA-mutated HR+/HER2- breast cancer.
View Biomarker - RET
RET
RET fusions in NSCLC and thyroid cancers. Targeted by selpercatinib and pralsetinib.
View Biomarker - FeaturedROS1
ROS1
Rare fusion driver in NSCLC. Targeted by crizotinib, entrectinib, repotrectinib.
View Biomarker - Featured
TMB High
Tumor Mutational Burden ≥10 mut/Mb. Indication for pembrolizumab across solid tumors.
View Biomarker - TP53
TP53
Most commonly mutated gene in cancer. Restored function via Gendicine (approved in China) for head and neck cancer.
View Biomarker - FeaturedEGFR
EGFR
Epidermal Growth Factor Receptor. Key driver in non-small cell lung cancer; targeted by osimertinib, erlotinib, gefitinib, and other TKIs.
View Biomarker